CATO 佳途CATO · CNAS + ANAB ISO 17034 双体系认可标准物质生产者CNAS + ANAB ISO 17034 dual-accredited reference material producer
销售顾问Sales contact 卢振明Kaka Lu+86 185 2048 1969kaka@cato-chem.com
Difluprednate

二氟泼尼酯 杂质对照品Difluprednate Impurities

10 个杂质条目10 impurity entries

本页汇总 二氟泼尼酯 的 10 个杂质对照品条目。杂质谱是仿制药杂质研究、方法开发与稳定性考察的起点——先锁定品种,再逐条比对结构差异与保留行为。This page collects 10 impurity reference standards of Difluprednate. The impurity profile is the starting point for related-substance method development, forced degradation and stability studies.

批量索取报价 / COABulk quote / COA在全站目录中检索Search the full catalogue

相关研究文献Related literature

以下为 二氟泼尼酯(Difluprednate)在公开文献中的研究报道(题录信息,来源 PubMed),供方法开发与文献调研参考。Selected peer-reviewed publications on this drug substance — bibliographic records from PubMed.

  1. 杂质研究Impurity studiesA multi-technique analytical approach for impurity profiling during synthesis: The case of difluprednate
    Journal of pharmaceutical and biomedical analysis · 2020 · Sammut Bartolo N et al.  ·  PMID 32814262  ·  DOI
  2. 杂质研究Impurity studiesHPLC-UV Method Development and Validation to Monitor Difluprednate Synthesis
    Journal of chromatographic science · 2023 · Sammut Bartolo N et al.  ·  PMID 36625195  ·  DOI
  3. 分析方法Analytical MethodsPhysicochemical characterisation of difluprednate and 6α9α-difluoroprednisolone: Determination of solubility, pKa and LogP
    Steroids · 2026 · Baluci G et al.  ·  PMID 42248441  ·  DOI
  4. 分析方法Analytical MethodsEvaluating critical quality attributes and novel drug release testing of difluprednate nanoemulsions
    International journal of pharmaceutics · 2025 · Palakurthi SS et al.  ·  PMID 40043965  ·  DOI
  5. 分析方法Analytical MethodsAnalysis of an anti-inflammatory steroidal drug, difluprednate, in aqueous humor by combination of semi-micro HPLC and column switching method
    Journal of pharmaceutical and biomedical analysis · 2003 · Yasueda S et al.  ·  PMID 12485714  ·  DOI

二氟泼尼酯 —— 原料药与杂质对照品Difluprednate — drug substance & impurities

共 11 个条目(含原料药本体)11 items incl. the drug substance
Difluprednate structure
原料药 APIAPI
二氟泼尼酯Difluprednate
Difluprednate
CAS No.23674-86-4
Chemical FormulaC27H34F2O7
Purity>95%询价On request
10mg25mg50mg100mg
Difluprednate Impurity 6 structure
6
二氟泼尼酯杂质6Difluprednate Impurity 6
Difluprednate Impurity 6
CAS No.167997-12-8
Chemical FormulaC20H24F2O4
Purity>95%询价On request
10mg25mg50mg100mg
Difluprednate Impurity 7 (21-Desacetyl Difluprednate) structure
7
二氟泼尼酯杂质7(21-去乙酰基二氟泼尼酯)Difluprednate Impurity 7 (21-Desacetyl Difluprednate)
Difluprednate Impurity 7 (21-Desacetyl Difluprednate)
CAS No.23640-96-2
Chemical FormulaC25H32F2O6
Purity>95%询价On request
10mg25mg50mg100mg
Difluprednate Impurity 11 structure
11
二氟泼尼酯杂质11Difluprednate Impurity 11
Difluprednate Impurity 11
CAS No.1270039-29-6
Chemical FormulaC21H24F2O4
Purity>95%询价On request
10mg25mg50mg100mg
Difluprednate Impurity 14 structure
14
二氟泼尼酯杂质14Difluprednate Impurity 14
Difluprednate Impurity 14
CAS No.1234557-20-0
Chemical FormulaC20H24F2O5
Purity>95%询价On request
10mg25mg50mg100mg
Difluprednate Impurity 15 structure
15
二氟泼尼酯杂质15Difluprednate Impurity 15
Difluprednate Impurity 15
CAS No.2285-44-1
Chemical FormulaC21H24F2O4
Purity>95%询价On request
10mg25mg50mg100mg
Difluprednate Impurity 16 structure
16
二氟泼尼酯杂质16Difluprednate Impurity 16
Difluprednate Impurity 16
CAS No.2326-26-3
Chemical FormulaC23H26F2O5
Purity>95%询价On request
10mg25mg50mg100mg
Difluprednate Impurity 17 structure
17
二氟泼尼酯杂质17Difluprednate Impurity 17
Difluprednate Impurity 17
CAS No.1296262-60-6
Chemical FormulaC21H24F2O5
Purity>95%询价On request
10mg25mg50mg100mg
Difluprednate Impurity 18 structure
18
二氟泼尼酯杂质18Difluprednate Impurity 18
Difluprednate Impurity 18
CAS No.806-29-1
Chemical FormulaC21H26F2O5
Purity>95%询价On request
10mg25mg50mg100mg
Difluprednate Impurity 20 structure
20
二氟泼尼酯杂质20Difluprednate Impurity 20
Difluprednate Impurity 20
CAS No.52-70-0
Chemical FormulaC23H28F2O6
Purity>95%询价On request
10mg25mg50mg100mg
Difluprednate Impurity 21 structure
21
二氟泼尼酯杂质21Difluprednate Impurity 21
Difluprednate Impurity 21
CAS No.51227-84-0
Chemical FormulaC27H36F2O7
Purity>95%询价On request
10mg25mg50mg100mg

结构式清晰度以随货 COA 与厂家图谱为准;目录之外的杂质可按需定制合成或调取。Structural confirmation is governed by the COA and manufacturer spectra. Impurities outside this list can be custom-synthesised or sourced on request.

Literature & synthesis

二氟泼尼酯 —— 研究文献与合成路线Difluprednate — literature & synthetic routes

以下题录由公开学术数据库按品种名检索汇总,供 二氟泼尼酯 的杂质谱研究、分析方法开发与工艺路线选择参考。文献题名与专利标题均可点击查看原文,版权归原作者与出版方所有。Citations below are aggregated from public scholarly databases by drug-substance name, for reference in impurity profiling, analytical method development and route selection for Difluprednate. Titles link to the original records; copyright remains with the authors and publishers.

杂质与降解研究文献Impurity & degradation studies

  1. Greenness and whiteness assessment of a sustainable voltammetric method for difluprednate estimation in the presence of its alkaline degradation product
    El-Hadi HRA, Eissa MS, Eltanany BM, et al. · Scientific reports · 2024 · 被引 8cited 8
  2. A multi-technique analytical approach for impurity profiling during synthesis: The case of difluprednate
    Sammut Bartolo N, Zoidis G, Gikas E, et al. · Journal of pharmaceutical and biomedical analysis · 2020 · 被引 3cited 3

合成与制备工艺专利Synthesis & process patents

  1. DIFLUPREDNATE PREPARATION
    NISHIJIMA SATOSHI, YAMAZAKI HIDEHITO, KATAYAMA MASAHIDE, SHIMIZU TOSHITO · 公开号 JP2005008569JP2005008569 · 2005
  2. AQUEOUS MEDICINAL PREPARATIONS FOR EXTERNAL USE CONTAINING SOLUBILIZED DIFLUPREDNATE
    YAMAGUCHI Masazumi, ISAKA Miyoko, INADA Katsuhiro · 公开号 WO9857646WO9857646 · 1998

题录与链接来自公开数据库 Europe PMC(含 PubMed 与全球专利题录)与 WIPO PatentScope,本站仅提供索引,不转载正文;如链接失效请以数据库检索为准。Citations are indexed from public databases (Europe PMC incl. PubMed and patent records, WIPO PatentScope); we provide links only and do not reproduce full text.

For formulation & analytical R&D

二氟泼尼酯 杂质谱研究要点Difluprednate — impurity profiling notes

下面这些是拿到 二氟泼尼酯 的 11 个杂质条目之后,仿制药研发最常遇到的几件事。先把杂质的来源分清,再决定要不要买对照品、买哪几个。Once you have the 11 impurity entries for Difluprednate, these are the questions that come up most in generic development. Classify the source of each impurity first, then decide which reference standards you actually need.

01工艺杂质Process impurities

起始物料、中间体、副产物、催化剂与溶剂残留。多来自合成路线本身,应在工艺开发阶段用加标试验定位。Starting materials, intermediates, by-products, catalysts and residual solvents — traced back to the synthetic route and located with spiking studies during process development.

02降解杂质Degradation impurities

水解、氧化、光解、高温高湿与聚合产物。需通过强制降解试验识别,并确认方法具备稳定性指示能力。Hydrolytic, oxidative, photolytic, thermal and polymeric degradants — identified through forced degradation, with the method proven stability-indicating.

03药典杂质Pharmacopoeial impurities

EP/USP 已收载并有官方编号的杂质(如 EP Impurity A、USP Related Compound B)。申报时通常需逐项对照。Impurities already monographed with official designations (e.g. EP Impurity A, USP Related Compound B), normally compared item by item during filing.

04基因毒性杂质Genotoxic impurities

含警示结构、需按 ICH M7 进行危害评估与限度推导(TTC 1.5 µg/日)。该类杂质必须用对照品准确控制。Structurally alerting compounds requiring ICH M7 hazard assessment and limit derivation (TTC 1.5 µg/day); these must be controlled with an authentic reference standard.

05同位素标记物Isotopically labelled standards

氘代、¹³C、¹⁵N 标记的同类物,主要用作 LC-MS/MS 生物分析的内标,抵消基质效应与回收率波动。Deuterated, ¹³C- and ¹⁵N-labelled analogues used as internal standards in LC-MS/MS bioanalysis to compensate matrix effects and recovery variation.

06代谢与转化产物Metabolites & conversion products

体内代谢物、强制降解转化物与工艺中间态,常见于杂质谱比对与稳定性考察中。In-vivo metabolites, forced-degradation products and process intermediates encountered in impurity profiling and stability studies.

方法开发与对照品使用建议Method development and standards usage

先定分离,再谈定量Resolution first, then quantification

主成分与相邻杂质峰分离度应 ≥1.5;用杂质对照品确定相对保留时间与相对响应因子,避免用自身对照法掩盖响应差异。Target baseline resolution ≥1.5 between the main component and adjacent impurities; establish relative retention and relative response factors with authentic impurity standards rather than relying on self-comparison.

校正因子不可忽略Never ignore response factors

紫外吸收差异大的杂质必须校正,否则定量结果系统性偏低或偏高。EP/USP 已给出校正因子的按药典执行。Impurities with markedly different UV response need correction, otherwise results are systematically biased. Where EP/USP publish a correction factor, follow the monograph.

强制降解要做全Run the full forced-degradation panel

建议覆盖酸、碱、氧化(H₂O₂)、光照(ICH Q1B)、高温高湿;主峰纯度用二极管阵列或质谱确认。Cover acid, base, peroxide oxidation, photostability (ICH Q1B) and heat/humidity; confirm peak purity by DAD or MS.

定义报告阈值Set reporting and identification thresholds

按 ICH Q3A/Q3B 设定报告阈值、鉴定阈值与界定阈值,避免为无意义的峰投入过多工作量。Apply ICH Q3A/Q3B reporting, identification and qualification thresholds so effort is not spent on insignificant peaks.

标准品储存有讲究Store standards properly

杂质对照品多建议 −20 ℃ 避光、干燥、密封保存;溶液现配现用,并记录开瓶与配制日期。Most impurity standards should be stored at −20 °C, protected from light and moisture; prepare solutions fresh and record opening and preparation dates.

用结构式先做初判Start from the structure

先比对杂质与主成分的结构差异,可预判其保留行为、紫外响应与可能的降解路径,能显著减少试错。Comparing the impurity structure with the parent drug predicts retention behaviour, UV response and probable degradation routes, cutting trial and error.

以上为通行的杂质研究实践提示,不针对具体品种给出结论。实际限度、校正因子与色谱条件请以 EP/USP 各论及你们的验证数据为准。需要某个杂质的结构确证资料、COA 或定制合成,可直接联系我们。The above are general impurity-profiling notes and are not conclusions about this specific drug substance. Actual limits, correction factors and chromatographic conditions follow the EP/USP monograph and your own validation data. Contact us for structural confirmation data, COAs or custom synthesis.
索取杂质谱报价 / COARequest a quote / COA← 查看其它品种← Other drug substances